MXPA97010478A - Use of an abstract of a non-photosintetic filamentosa bacteria and composition that the conti - Google Patents

Abstract

The present invention relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium as a substance P antagonist, in a cosmetic composition or for the preparation of a cosmetic composition or for the preparation of a pharmaceutical composition. The invention also relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic composition or for the preparation of a pharmaceutical composition intended to treat disorders associated with an excess of synthesis and / or substance release. P. The invention also relates to various compositions containing an extract of at least one non-photosynthetic filamentous bacterium and a cosmetic treatment method.

Description

USING AN ABSTRACT OF A FILAMENTARY BACTERIA NO PHOTOSINTETICA AND COMPOSITION THAT CONTAINS IT The present invention relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium as a substance P antagonist, in a cosmetic composition or for the preparation of a pharmaceutical composition. The invention also relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic composition or for the preparation of a pharmaceutical composition intended to treat disorders associated with an excess of synthesis and / or release of substance P. The invention also relates to various compositions containing an extract of at least one non-photosynthetic filamentous bacterium and to a cosmetic treatment process.

There are polypeptides in mammals that belong to the family of tachykinins that induce rapid contractions in muscle fibers. Among the compounds of this family, mention may be made of neurokinin-β, neurokinin-a and substance P. Substance P is a polypeptide chemical element (a decapeptide), produced and released by a nerve ending. The location of substance P is specific to neurons, both in the central nervous system and in the REF: 26292 organs of the periphery. Thus, numerous organs or tissues receive the afferents of neurons of substance P, namely the salivary glands, the stomach, the pancreas, the intestine (in this case, the distribution of substance P overlaps the intrinsic nerve plexus of Meissner and of Auerbach), of the cardio-vascular system, of the thyroid gland, of the skin, of the iris and of the ciliary bodies, of the bladder and evidently of the central and peripheral nervous systems. Due to the ubiquitous distribution of substance P, numerous disorders are associated with an excess of synthesis and / or release of substance P. Substance P intervenes in particular in the transmission of pain and in diseases of the central nervous system (for example anxiety, psychosis, neuropathies, neurodegenerative disorders of the senile dementia type of Alzheimer's, dementia of the sidoses, Parkinson's disease, Down syndrome, Korsakoff's syndrome, multiple sclerosis, schizophrenia), in respiratory diseases (such as, for example, bronchial pneumonias) and inflammatory (such as for example rheumatoid polyarthritis), in allergic syndromes (such as for example asthma, allergic rhinitis, allergic pharyngitis, urticaria, eczematous dermatitis), in gastrointestinal diseases (such as, for example, ulcers, colitis, Crohn's disease), in skin disorders (such as, for example, psoria asis, pruritic diseases, herpes, photoderostasis, atopic dermatitis, contact dermatitis, lichen, prurigo, pruritus, insect bites), in fibrosis and other alterations in the maturation of collagens (such as for example sclerodermis), in cardiovascular disorders, in vasoesphasic disorders (such as for example migraines, Reynaud's disease), in immune disorders, in urinary tract disorders (such as incontinence, cystitis, for example) , in rheumatic diseases, in some dermatological diseases (such as eczema) and in the affections of drugs (such as, for example, conjunctivitis, uveitis, ocular itching, eye pain and irritation). The use of substance P antagonist is one of the effective therapeutic alternatives in all the conditions mentioned above. By substance P antagonist is meant any compound capable of partially or even completely inhibiting the biological effect of substance P. Particularly, for a substance to be recognized as a substance P antagonist it must induce a coherent pharmacological response (including or not its attachment to the substance P receptor) particularly in one of the following tests: the antagonist must decrease extravasation of plasma through the vascular wall induced by capsaicin or by antidromic nerve stimulation, or - the antagonist must cause an inhibition of smooth muscle contraction induced by the administration of the substance P. Until today, substance P antagonists are used to treat the disorders indicated above. In this regard, reference can be made to documents US-A-4472305, US-A-4839465, EP-A-101929, EP-A-333174, EP-A-336230, EP-A-394989, EP-A -498069, EP-A-515681, EP-A-57589, OA-92/22569, GB-A-2216529, EP-A-360390, EP-A-429366, EP-A-430771, EP-A-499313 , EP-A-514273, EP-A-514274, EP-A-514275, EP-A-514276, EP-A-520555, EP-A-528495, EP-A-532456, EP-A-545478, EP -A-558156, OA-90/05525, WO-A-90/05729, WO-A-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585 , WO-A-93/01159, OA-93/01169, WO-A-93/01170, WO-A-93/06099, WO-A-93/09116, EP-A-522808, WO-A-93 / 1165. However none of these documents considers, nor suggests that an extract of at least one non-photosynthetic filamentous bacterium can have a substance P antagonist activity as defined above and therefore can be particularly used to treat the disorders indicated above. The applicant has discovered that a stratum of non-photosynthetic filamentous bacteria responds to the characteristics defined as characterizing a substance P antagonist and can therefore be used as substance P antagonist. Thus, the invention relates to the use of at least an extract of at least one non-photosynthetic filamentous bacterium as an antagonist of substance P in a cosmetic composition or for the preparation of a pharmaceutical composition. The invention also relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic composition or for the preparation of a pharmaceutical composition intended to treat disorders associated with an excess of synthesis and / or substance release. P. By extract of non-photosynthetic filamentous bacteria, is meant both the supernatant of the culture of said bacteria, the biomass obtained after the culture of said bacteria or even the extracts of the biomass obtained by treatment of this biomass. The bacterial extracts according to the invention are prepared from non-photosynthetic filamentous bacteria such as those defined according to the classification of Bergey's Manual of Systematic Bacteriology (vol.3, sections 22 and 23, 9th edition, 1989), among which cite the bacteria belonging to the order of the Beggiatoales, and more particularly to the bacteria belonging to the genera Beggiatoa, Vitreoscilla, Flexithrix and Leucothrix. The bacteria that have just been defined and of which several have already been described generally have an aquatic habitat and can be found particularly in marine waters or in thermal waters. Among the usable bacteria there may be mentioned for example: Vitreo? Illa fi fOrmig (ATCC 15551) Vitreoscilla filiformis (ATCC43181) Beggiatoa alba (ATCC 33555) Flexithrix dorotheae (ATCC 23163) Leucothrix mucor (ATCC 25107) Sphaerotilus natans (ATCC 13338) Preferably, a strain of Vitreoscilla filiformis is used according to the invention. To prepare the extract according to the invention, said bacteria can be cultured according to methods known to those skilled in the art, and then separated from the biomass obtained, for example by filtration, centrifugation, coagulation and / or lyophilization. Particularly useful extracts according to the invention can be prepared according to the process described by the applicant in the patent application WO-A-93/00741. Thus, after cultivation, the bacteria are concentrated by centrifugation. The biomass obtained is autoclaved. This biomass can be lyophilized to constitute what is called the lyophilized extract. Any lyophilization method known to the person skilled in the art can be used to prepare this extract. The supernatant fraction of this biomass can also be filtered in a sterile container to remove the particles in suspension, thus obtaining the extract called on the other side of the text aqueous extract. Whatever its form used in the invention, the amount of bacterial extract according to the invention contained in the composition is well understood depending on the desired effect and can therefore vary greatly. To provide an order of magnitude in a cosmetic composition said bacterial extract is used in an amount representing from 0.0001% to 20% of the total weight of the composition and preferably in an amount representing 0.001% to 10% of the total weight of the composition. the composition. To provide an order of magnitude in a pharmaceutical composition said bacterial extract an amount representing 0.0001% to 30% of the total weight of the composition and preferably in an amount representing 0.05% to 20% of the total weight of the composition is used. composition.

The examples of disorders related to an excess of synthesis and / or release of substance P. have been previously seen in the text. Thus, according to a particular aspect, the invention has for its object the use of at least one extract of at least one bacterium non-photosynthetic filament in a cosmetic composition or for the preparation of a pharmaceutical composition intended for preparing disorders of the central nervous system, 'respiratory problems, allergic syndromes, inflammation, pain, gastrointestinal disorders, skin disorders, fibrosis , alterations in the maturation of collagen, cardiovascular problems, vasospastic problems, immune disorders as well as urinary tract problems in the field of skin disorders, it is known that certain skins are more sensitive than others. It is known that there are numerous phenomena of intolerance at the skin level whose symptoms are in particular the subjective signs that are essentially dysesthetic sensations. Disesthetic sensations are understood as the more or less painful sensations felt in a cutaneous area such as stitches, tingling, itching or itching, burns, irritations, discomforts, strains, etc.

These phenomena can be the consequence of multiple events of which the most common will be classified as irritation or inflammation, but some of which will be due to physiological causes, such as sensitive skins, even pathological such as, for example, allergy. However the symptoms of sensitive skin were so far poorly characterized and the problem of these skins was, for this reason, poorly defined, no one knew exactly the process produced in the sensitivity of the skin. Some thought that a sensitive skin was a skin that reacted to cosmetic products, others that it was a skin that reacted to several external factors, not necessarily related to cosmetic products. Sensitive skin was also assimilated with allergic skin. The tests have been put in place to delimit the sensitive skins, for example tests with lactic acid DMSO which are known to be irritating substances: see for example the article by K. Lammintausta et al., Dermatoses, 1988, 1 £, pages 45-49, and the article by T. Agner et J. Serup, Clinical and Experimental Dermatology, 1989 14. pages 214-217. Due to the ignorance of the characteristics of the sensitive skins, until now it was very difficult even impossible to treat them. In fact, they were treated indirectly, for example, by limiting the use of irritants such as surfactants, preservatives or perfumes, or the use of certain cosmetic or dermatological active agents in cosmetic or dermatological compositions. After numerous clinical trials, the applicant firm has been able to determine the symptoms related to sensitive skin. The applicant firm has found that sensitive skins can be divided into two large clinical forms, irritable and / or reactive skins, and intolerant skins. An irritable and / or reactive skin is a skin that reacts by itching, that is, by itching, or by pickets to different factors such as the environment, emotions, food, wind, friction, the razor, the soap, surfactants, hard water with strong calcareous concentration, temperature variations or wool. In general, these signs are associated with dry skin with or without herpes, or with skin that presents an erythema. An intolerant skin is a skin that reacts by sensations of irritation, strains, tingling and / or red spots, to different factors such as the environment, emotions, food and certain cosmetic products. In general, these signs are associated with hyperseborrhoeic or acneic skin with or without herpes, and to an erythema. These phenomena can be generalized to the whole body, but most of the time they can have well-defined locations such as the scalp, face, skin wrinkles, etc ... "Sensitive" scalps have a more univocal clinical semiology: the sensations of itching and / or itching and / or irritation are triggered essentially by local factors such as friction, soap, surfactants, hard water with strong limestone concentration, shampoos or lotions. These sensations are also triggered sometimes by factors such as the environment, emotions and / or food. An erythema and a hyperseborrhea of the scalp as well as a peculiar state are frequently associated with the preceding signs. On the other hand, in certain anatomical regions such as large wrinkles (inguinal, genital, axillary, popliteal, anal, sub-marine, elbow wrinkles) and feet, sensitive skin is translated by pruritic sensations and / or dysesthetic sensations ( irritations, itching) related in particular to sweat, friction, wool, surfactants, certain cosmetic preparations, hard water with a high calcareous concentration and / or temperature variations. The whole of these phenomena of intolerance is always related to a classic inflammatory process, and more particularly to an inflammatory reaction of neurogenic type since the cutaneous nerve fibers intervene. The applicant firm was also able to show that a sensitive skin was not an allergic skin. In effect, an allergic skin is a skin that reacts with an external agent, an allergen, which triggers an allergic reaction. It is an immunological process that only occurs when an allergen is present and that only affects sensitized subjects. On the contrary, the final result of an allergic reaction is also translated by an acute inflammatory reaction generally associated with an edema. The essential characteristic of sensitive skin is, according to the applicant, on the contrary, a mechanism of response to external factors, which can affect any individual, even if the so-called sensitive skin individuals react faster than the others. This mechanism is not immunological, it is non-specific. Whatever the phenomenon considered, there is a point common to all these mechanisms that is translated by an inflammatory reaction whose terminal facet is measured by the release by the mastocyte cells of the skin of at least one mediator of inflammation such as histamine, serotonin, heparin, leukotrienes, prostaglandins, cytokines, nitrogen monoxide or reactive oxygen species. To determine whether a skin is sensitive or not, the applicant has also placed an essay. In fact, after having carried out a large number of tests in order to define a sensitive skin, it was surprisingly found that there was a relationship between people with sensitive skin and those who reacted to a topical application of capsaicin. The test with capsaicin consists of applying on approximately 4 cm of skin 0.05 ml of a cream containing 0.075% of capsaicin and observing the appearance, such as stings, burns and itching. In subjects with sensitive skin, these signs appear between 3 and 20 minutes after application and are followed by the appearance of an "erythema that begins in the periphery of the application area." Until now, capsaicin was used as a medicine, In particular to treat the pains of the area Capsaicin causes a release of neuropeptides, and in particular of tachykinins that come from the nerve endings of the epidermis and the dermis.The applicant has observed that the physiopathological scheme common to all sensitive skin states was related to a great ability to release tachykinins and more particularly the substance P in the skin.The dysesthetic manifestations that are caused by their release are called "neurogenic." No one has yet established a relationship between substance P and sensitive skin The clinical signs of sensitive skin are essentially subjective: itching, tingling, pruritus, tightness, irritation, and sometimes associated with erythema. These signs are due to non-specific external factors. The symptoms appear essentially localized in the face, in the neck and in the scalp, but they can also appear throughout the body. Thus, the applicant has discovered that one of the essential characteristics of sensitive skin is related to the release of substance P and therefore that the use of substance P antagonists may allow a preventive and / or curative effect of sensitive skin. . In order to treat sensitive skin, the applicant has therefore considered using substance P antagonists. Indeed, it has surprisingly observed that the incorporation of a substance P antagonist in a composition intended for topical use makes it possible to avoid irritation and / or irritation. the dysesthetic sensations and / or the pruritus of the skin. The invention thus relates more particularly to the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic composition or for the preparation of a pharmaceutical composition intended to treat sensitive skins. The subject of the present invention is also the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic composition or for the preparation of a pharmaceutical composition intended to prevent and / or to combat skin irritations and / or herpes and / or erythemas and / or sensations of irritation and / or dysesthesia and / or pruritus of the skin and / or mucous membranes. Advantageously, according to the invention, at least one extract of at least one non-photosynthetic filamentous bacterium can be associated with irritant effect products commonly used in the cosmetic or pharmaceutical field, products that are sometimes cosmetic or pharmaceutical active agents. The presence of a substance P antagonist in the form of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic or pharmaceutical composition comprising a product having an irritant effect allows to strongly attenuate, even suppress this irritant effect. This also makes it possible to increase the amount of active principle of irritant effect in relation to the amount of active principle normally used, in view of an improved efficiency. Thus, the invention also relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a cosmetic or pharmaceutical composition further comprising at least one product with an irritant effect. The invention also relates to a cosmetic or pharmaceutical composition comprising, in a cosmetically or pharmaceutically acceptable medium, at least one extract of at least non-photosynthetic filamentous bacteria and also at least one product with an irritant effect. As an irritant, mention may be made, for example, of surfactants (ionic or non-ionic), preservatives, organic solvents or active agents such as ar-hydroxy-acids (citric, malic, glycolic, tartaric, mandelic, lactic acid). ), ß-hydroxy acids (salicylic acid and its derivatives), a-keto acids, ß-ketoacids, retinoids (retinol, retinal, retinoic acid), anthralins (dioxiantranol), anthranoids, peroxides (particularly benzoyl), minoxidil, lithium salts, antimetabolites, ceratolytics, vitamin D and its derivatives, dyes or hair dyes (paraphenylenediamine and its derivatives, aminophenols), perfumed alcohol solutions (perfumes, cologne waters, aftershave lotions, deodorants), antiperspirant agents (some aluminum salts), depilatory or permanent hair active agents (thiols), active agents after igmentants (hydroquinone). The use of substance P antagonist makes it possible in particular to multiply by 2 to 10 times the quantity of active ingredient with an irritant effect in relation to the state of the art., without feeling all the discomforts mentioned above. Thus, the hydroxy acids can be used up to 50% by weight of the composition or the retinoids up to 5%, notably decreasing their irritant nature.

In some cases, the whole mechanism is also under the control of the sensory nerve endings released by neuropeptides, particularly substance P and CGRP. CGRP, a peptide derived from calcitonin (known under the name of Calcitonine Gene Related Peptide or CGRP) is a polypeptide chemical element made and released by a nerve ending. The location of the CGPR is specific to the sensory nerve fibers (C fibers). Thus, numerous organs or tissues receive afferents from CGPR neurons, particularly the salivary glands, the stomach, the pancreas, the intestine, the cardio-vascular system, the thyroid gland and the skin. Another objective of the present invention is to obtain the widest possible beneficial effect in the treatment of all cases of cutaneous affections and therefore to propose a composition that acts on several components of these affections. Thus, according to another aspect, the present invention aims at the use of at least one extract of a non-photosynthetic filamentous bacterium as described above in a cosmetic or pharmaceutical composition also containing at least one cell extract of at least one a vegetable of the family of Iridáceas. According to one aspect, the present invention has for its object a cosmetic or pharmaceutical composition, characterized in that it contains, in a cosmetically or pharmaceutically appropriate medium, an extract of at least one non-photosynthetic filamentous bacterium as described above and an extract of plant material of at least one Iridácea. The extract of at least one Iridácea can be any extract prepared from the vegetal material that results from the family of the Iridaceae. The composition may contain an extract of at least one Iridide obtained from plant material resulting from the whole plant grown in vivo or resulting from the in vitro culture. Thus, for example according to the invention, the extract can be an extract of an organ including cells of the organ of at least one Iridácea (roots, stem, leaves) or alternatively an extract of undifferentiated cells of at least one Iridácea. Preferably, an extract obtained from undifferentiated cells obtained by in vivo or in vitro culture is used. The selection pressure imposed by the physicochemical conditions during the growth of plant cells in vitro makes it possible to obtain a standardized vegetable material available throughout throughout the year contrary to plants grown in vivo. By in vitro culture. it is understood the set of techniques known by the expert that allow artificially obtaining a vegetable or part of a vegetable. Thus, for example, according to the invention, an extract of roots of at least one Iridácea cultivated in vitro or alternatively an extract of undifferentiated cells of at least one Iridácea can be used. Preferably, an extract obtained from plant material cultivated in vitro and even more preferably an extract obtained from undifferentiated cells cultured in vitro is used. By undifferentiated plant cells, any plant cell is understood that does not have any particular specialization characteristic and capable of living by itself and not in dependence on other cells. These undifferentiated plant cells are eventually capable, under the effect of an induction, of any differentiation according to their genome. According to the chosen culture method, and in particular according to the chosen culture medium, it is possible to obtain, from a single explant, the undifferentiated plant cells that have different characteristics. The family of the Iridáceas (or Irideas) includes approximately 750 species. The plants of the Iridáceas family are used especially for their aromatic and ornamental properties.

Among the genera of Iridáceas used according to the invention, we can mention by way of example the genera of Romulea, Crocus, Iris, Gladiolus, Sisyrinchium or alternatively Hermodactylus. As useful plant material we can mention the one that comes from I is ermánica, Iris florentina, Iris pallida, Croc s versicolor, Romulea bulbucodium or alternatively Gladiolus communis. More particularly, according to the invention, plant material resulting from the Iris genus and preferentially plant material from Iris pallida is used. Any extraction method known to those skilled in the art can be used to prepare the extract contained in the composition according to the invention. It is possible, in particular, to mention the alcoholic extracts, particularly ethanolic or even hydroalcoholic. An extract prepared by the method described in French patent application No. 95-02379 filed by the applicant may also be used. Thus, in a first stage the vegetable material is ground in a cold aqueous solution, in a second stage the suspended particles are removed from the aqueous solution resulting from the first stage, and in a third stage the resulting aqueous solution is sterilized. of the second stage. This aqueous solution corresponds to the extract. In addition, the first step can be advantageously replaced by a simple freezing operation of the plant tissues (for example at 20 ° C), followed by an aqueous extraction which summarizes the second and third steps described above. An example of preparing Iridáceas useful according to the invention is also given in the examples. The amount of extract contained in the composition of the invention is well understood depending on the effect sought and can thus vary to a large extent. To give an order of magnitude, if the composition is a cosmetic composition, it may contain an extract of at least one Iridace in an amount representing 0.001% to 20% of the total weight of the composition and preferentially in an amount representing 0.01% to 10% of the total weight of the composition. To give an order of magnitude, if the composition is a pharmaceutical composition, it may contain an extract of at least one Iridace in an amount representing 0.01% to 30% of the total weight of the composition and preferentially in an amount representing 0.05% to 20% of the total weight of the composition. According to another aspect, the present invention aims at the use of an extract of at least one non-photosynthetic filamentous bacterium as described above in a cosmetic or pharmaceutical composition also containing at least one compound that decreases the synthesis, release and / or the activity of at least one mediator of inflammation with the exception of steroidal and nonsteroidal anti-inflammatory agents. The invention also relates to a cosmetic or pharmaceutical composition characterized in that it contains, in a cosmetically or pharmaceutically acceptable medium, an extract of at least one non-photosynthetic filamentous bacterium as described above and a compound that decreases the synthesis, release and / or the activity of at least one mediator of inflammation with the exception of steroidal and nonsteroidal anti-inflammatory agents. Among the steroidal anti-inflammatory agents, mention may be made, for example, of hydrocortizone, betamethasone valerate or clobetazole propionate. By non-steroidal anti-inflammatory agents, it is understood here the anti-inflammatory agents such as those described by Schorderet and Dayer in Pharmacology, "Des concepts fondamentaux aux applications thérapeutiques", 1992, chapter 37, pages 541-561, 2nd edition, Frison-Roche / Slatkine editors. These are arylcarboxylic acids, such as salicylic acid derivatives or anthranilic acid derivatives, of arylalcanic acids, such as arylacetic and heteroarylactic acids or arylpropionic acids, of enolic acids such as pyrazolone derivatives or oxicam, and non-acid derivatives, such as for example bufexamac (Merck Index, llava edition (MI) 1462), benzidamine (MI 1136), epirizol (MI 3572), fluprocuazone (MI 4120) or thiaramide (MI 9356).

Preferably, the composition according to the invention comprises a compound that decreases the synthesis, release and / or activity of at least one mediator of cutaneous inflammation in association with an extract of at least one non-photosynthetic filamentous bacterium. The compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation is preferably chosen among agonists of substance P and / or of CGRP, inhibitors of NO-synthase, bradykinin antagonists, cytokine antagonists, antagonists of histamine, antagonists of tumor necrosis factor type a (TNFa).

For example, according to the invention, one or more substance P antagonists selected from peptides, non-peptide compounds such as those comprising at least one heterocycle, hydrogenated compounds comprising at least one benzene ring, hot springs, and its mixtures It can be used in the invention, for example, as peptide antagonist of substance P sequestered and spastid II. The setad corresponds to the formula: Tyr D-Phe Phe D-His Leu Met NH3 in which: Tyr represents tyrosine, D-Phe represents D-phenylalanine, Phe represents phenylalanine, D-His represents D-histidine, Leu represents leucine, Met represents methionine. The fright corresponds to the formula: D-NicLys Pro 3 -Pal Pro D-Cl2Phe Asn D-Trp Phe D-Trp Leu Nle NH2 in which: D-NicLys represents the nicotinate of D-lysine, Pro represents proline, 3 -Pal represents 3-pyridyl-alanine, D-CL2Phe represents D-dichlorophenylalanine, Asn represents asparagine, D- Trp represents tryptophan, Phe represents phenylalanine, Leu represents leucine, Nle represents norleucine. The peptides described in US-A-4472305, US-A-4839465, EP-A-101929, EP-A-333174, EP-A-336230 can also be used in the invention as the substance P antagonist peptide. , EP-A-394989, EP-A-443132, EP-A-498069, EP-A-515681, EP-A-517589, WO-A-92/22569 and GB-A-2216529. The nonpeptide substance P antagonists which can be used in the invention are, in particular, the compounds comprising a heteroatom linked directly or indirectly to a benzene ring or a heterocycle. In particular, this heteroatom is an oxygen, hydrogen or sulfur atom. As the heterocyclic compound, those described in the following documents can be used in particular in the invention: EP-A-360390, EP-A-429366, EP-A-430771, EP-A-499313, EP-A-514273, EP -A-514274, EP-A-514275, EP-A-514276, EP-A-520555, EP-A-528495, EP-A-532456, EP-A-545478, EP-A-558156, OA-90 / 05525, OA-90/05729, OA-91/18878, WO-A-91/18899, WO-A-92/12151, WO-A-92/15585, OA-92/17449, WO-A-92 / 20676, WO-A-93/00330, WO-A-93/00331, WO-A-93/01159, WO-A-93/01169, WO-A-93/01170, O-A-93/06099 , WO-A-93/09116. In particular, the compound containing at least one hydrogenated heterocycle is a 2-tricyclic-2-amino-ethane derivative, a spirolactam derivative, a quinuclidine derivative, an azacyclic derivative, an aminopyrrolidine derivative, a piperidine derivative, an aminoazaheterocycle or an isoindol derivative. As other heterocyclic compounds, mention may be made of oxygenated or sulfur-containing heterocyclic compounds such as furan derivatives, benzofuran derivatives, thiophene derivatives and benzothiophene derivatives, optionally containing the nitrogenous substituents, such as the heterocyclic compounds described in US-A-4931459, US-A-4910317 and EP-A-299457, and more especially the alkoxy and / or aryloxy-tetrazolyl-benzofuran-carboxamides or the alkoxy and / or aryloxy-tetrazolyl-benzothiophene-carboxamides. As compounds containing a hydrogen atom attached directly or indirectly to a benzene ring, there may be mentioned those described in the following documents: EP-A-522808 and O-A-93/01165 and WO-A-93/10073. The salts of cations useful in the invention are in particular the strontium salts, magnesium, lanthanides that have atomic number from 57 to 71, cobalt, nickel, manganese, barium, yttrium, copper, tin, rubidium, lithium and zinc. These salts can be, for example, carbonates, salicylates, bicarbonates, sulphates, glycerophosphates, borates, chlorides, nitrates, acetates, hydroxides, persulfates as well as salts of hydroxy acids (citrates, tartrates, lactates, malate) or fruit acids, or even of salts of amino acids (aspartate, arginate, glycolate, fumarate) or salts of fatty acids (palmitate, oleate, caseinate, behenate). Preferably, the salt is chosen from strontium, manganese, yttrium or magnesium nitrate, strontium borate, manganese, yttrium or magnesium, strontium chloride, manganese or magnesium, magnesium sulfate, manganese or strontium. Even more preferably, these salts are strontium chloride or nitrate. Among the thermal waters useful according to the invention, one can mention more particularly the hot springs of the Vichy source, such as those coming from the sources Célestins, Chomel, Grande-Grille, Hópital, Lucas and Stop Preferably, according to the invention, water from the Lucas source is used. Substance P antagonists can be used alone or as a mixture. By CGRP antagonist, any compound capable of partially or even totally inhibiting the biological effect of CGRP is understood. Particularly, for a substance to be recognized as a CGRP antagonist it must induce a coherent pharmacological response (including its attachment to the CGRP receptor) in particular in one of the following tests: + the antagonist substance must decrease vasodilation induced by capsaicin and / or an antidromic electrical stimulation (applied to an afferent nerve) and / or + the antagonist must cause an inhibition of the release of CGRP by the sensitive nerve fibers and / or + the antagonist must cause an inhibition of contraction of smooth muscle of the vas deferens induced by CGRP. Among the known antagonists of CGRP, there may be mentioned, for example, CGRP 8-37 (amino acid sequence 8 to 37 of the N-terminal part of CGRP), or even anti-CGRP antibodies. The CGRP antagonists can be used alone or as a mixture. The term NO-synthase does in fact cover a family of enzymes that, specifically, provide the enzymatic catalysis of L-arginine in citrulline, during the catalysis of this a gaseous mediator with multiple functions, nitrogen monoxide or NO is produced. Nitrogen monoxide has a supplementary electron that makes it extremely reactive chemically. It is well known that such compounds are harmful and it is sought to limit their production as much as possible. This is how in the case of nitrogen monoxide NO-synthase inhibitors have been studied extensively. Thus, according to the invention, NO synthase inhibitors are the products that allow in situ in man to partially or even completely inhibit the synthesis of nitrogen monoxide (NO). These are therefore compounds chosen from compounds that inhibit synthesis and / or accelerate the catabolism of NO-synthase, the compounds that neutralize NO-synthase or the compounds involved in decreasing the signal transduced by NO-synthase. .

Thus, the NO-synthase inhibitor can be chosen between synthetic or natural, optionally modified peptides, chemical, synthetic or natural molecules, antisense nucleic acids, ribozymes, anti-NO-synthase antibodies. Among these NO-synthase inhibitors, mention may be made in particular of N -monomethyl-L-arginine (L-NMMA), N-nitro-L-arginine, the methylated ester of N-Nitro-L- arginine, diphenyleniodonium chloride, 7-nitroindazole, N (5) - (l-iminoethyl) -L-ornithine, KP ^ -dimethyl-L-arginine, N ^ I ^ -dimethyl-arginine, 2- (4-carboxyphenyl) -4,4,5,5-tetramethylimidazoline-l-oxyl-3-oxide, aminoguanidine, canavanine, ebselen and melanocyte-stimulating hormone type c *. Among the NO-synthase inhibitors, the N-monomethyl-L-arginine and the melanocyte-stimulating hormone type a are preferably used. The NO-synthase inhibitors can be used alone or in a mixture. Bradydicine is a peptide of plasma origin released from a kininogen precursor by a plasma protease called Kalicrein (EC 3.4.21.24). This nanopeptide is one of the key mediators of inflammation and possesses mitogenic properties. The receptors for this kinin are divided into two main subtypes, Bl and B2. Bradykinin acts particularly on the B2 receptor and causes the stimulation of numerous secondary messenger production systems including the hydrolysis of inositol phosphates, arachidonic acid metabolism, phosphorylation of tyrosine residues as well as depolarization or hyperpolarization of the membrane cell phone. The activation of certain receptors causes the activation of phospholipase C and thus the production of inositol 1, 4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 is known to cause the release of calcium from intracellular storage sites within cells including the ceratinocyte. Calcium, described as an activator and regulator of numerous enzymes (proteases, phospholipases), plays an important role in regulating the differentiation and proliferation of ceratinocytes. By bradykinin antagonist, is meant any compound capable of partially or even totally inhibiting the biological effect of bradykinin. Particularly, for a substance to be recognized as an antagonist of bradykinin it must induce a coherent pharmacological response that includes or not its binding to the bradykinin receptor. Thus, within this definition, any compound that may interfere with the effects of bradykinin by its binding to the receptor thereof (Bl or B2) and / or any compound that independently of the binding to the receptor (s) induces any mechanism an effect contrary to the known bradykinin (for example that interferes with the synthesis of bradykinin). Among bradykinin antagonists, it is preferred to use compounds that inhibit synthesis and / or accelerate the catabolism of bradykinin, compounds that neutralize bradykinin, compounds that block bradykinin receptors such as those that interfere with bradykinin. effects of bradykinin by its binding to the receptor thereof (Bl or B2), compounds that inhibit the synthesis of bradykinin receptors or compounds that intervene by decreasing the signal transduced by bradykinin. These compounds can be of natural or synthetic origin. Among the bradykinin antagonists, mention may be made more particularly of peptides, synthetic or natural, optionally modified, such as D-Arg, [Hyp3, D-Phe7] -bradicinin (NPC567), [Thi5.8, D-Phe7] ] -bradicinin, D-Arg, [Hyp'3, Thi 5,8, D-Phe7] -bradicinin, N-cu-adamantanoacetyl-D-Arg, [Hyp3, Thi 5,8, D-Phe7] - bradydinin, des-Arg9, [Leu8] -bradicinin (all sold by the company Sigma) or even the compounds cited in patents WO 95/08566, WO 95/07294, EP 0623350, EP 0622361, WO 94/11021, EP0596406 , WO 94/06453, WO 94/09001, EP 0578521, EP 0564972, EP 0552106, WO 93/11789, US 5216165, US 5212182, WO 92/17201, EP 0496369, EP0472220, EP 0455133, WO 91/09055, WO 91/02746, EP 0413277, EP 0370453, EP 0359310, WO 90/03980, WO 89/09231, WO 89/09230, WO 89/01780, EP 0334244, EP 0596406, WO 86/07263 or P-guanidobenzoyl, [ Hyp3, Thi5, D-Tic7, Oic8] bradydinin (S 16118) (Feletou M & amp;; al., Pharmacol. Exp. Ther., June 1995, 273, 1078-84), D-Arg, [Hyp3, Thi5, D-Tic7.0ic8] -bradycinin (HOE 140) (Feletou M &al., Eur. J. Pharmacol 1995, 274, 57-64), D-Arg, [Hyp3, Hype (trans-propyl) 7, Oic 8] -bradicinin (NPC 17731) (Herzig MCS and Leeb-Lundberg LMF, J. Biol. Chem. 1995, 270, 20591-20598) or even cited in Bradikinin Agonists: development and applications (Stewart JM, Biopolymers, 1995, 37, 143-155), or even chemical, synthetic or natural molecules, such as those described in Salvino et al. J. Med. Chem., 1993, 36, 2583-2584. Antisense nucleic acids or ribozymes which aim to selectively inhibit the synthesis of bradykinin can also be used according to the invention. These antisense nucleic acids are known to the person skilled in the art. These can act in different ways on the DNA or on the messenger RNA that codes for bradykinin, in particular to block the binding or progression of the ribosomes along the messenger RNA, to cut the messenger RNA by the RNase H, or by avoiding the transport of messenger RNA from the nucleus to the cytoplasm or even preventing the maturation of messenger RNA. Anti-bradykinin antibodies or soluble bradykinin receptors, anti-bradykinin receptor antibodies or bradykinin receptor antagonists can still be used according to the invention. Preferably, according to the invention, a compound is used that interferes with the effects of bradykinin by its binding to the receptor thereof (Bl or B2), preferably to the B2 receptor. Still more preferably, a bradykinin antagonist chosen from among: D-Arg, [Hy? 3, D-Phe7] -bradicinin (NPC567), [Thi 5.8, D-Phe7] is used according to the invention. ] -bradicinin, D-Arg, [Hyp3, Thi 5.8, D-Phe7] -bradicinin, N-OI-adamantanoacetyl-D-Arg, [Hyp3, Thi 5.8, D-Phe7] -bradicinin, the des-Arg9, [Leu8] -bradicinin, the P-guanidobenzoyl, [Hyp3, Thi5, D-Tic7, Oic8] radicinin (S 16118), D-Arg, [Hyp3, Thi5, D-Tic7, Oic8] -bradycinin (HOE 140), D-Arg, [Hyp3, Hype. { trans-propyl) 7, Oic 8] -bradicinin (NPC 17731). The modified peptide preferably used is D-Arg, [Hyp3, Thi5, D-Tic7, Oic8] -brahiminin (HOE 140). The bradykinin antagonists can be used alone or in admixture.

It is also said that the substance P released by the sensitive epidermal terminations induces a cascade of biochemical events where the first stages are located at the level of mast cells. The fixation of substance P on mastocyte receptors induces a release of numerous pro-inflammatory mediators among those who are histamine, cytokines such as interleukin 1 (IL1), interleukin 6 (IL6), interleukin 8 (IL8) and tumor necrosis factor of type or? Tumor Necrosis Factor a (TNF-a;)). By "histamine antagonist", cytokines and / or TNF-a ?, is meant all substances capable of inhibiting the release and / or synthesis and / or binding of the histamine receptor, cytokines and / or TNF-a : Antagonists that inhibit the binding of the histamine receptor are the specific agents of the histamine type 1 receptor (Hl). For a substance to be recognized as a receptor antagonist of histamine, cytokines or TNF-a, it must respond to one of the following characteristics: - have an affinity for the specific receptors of these compounds; - have a pharmacological activity antagonist of the histamine receptor, cytokines or TNF-a, ie induce a consistent pharmacological response in one of the following tests: + for histamine receptor antagonists: an inhibition of smooth muscle contraction induced by the administration of histamine; + for cytokine receptor antagonists: inhibition of macrophage adhesion induced by cytokines in endothelial cells or inhibition of superoxide anion release induced by cytokines with respect to neutrophils; + for antagonists of TNF-a receptors: inhibition of macrophage adhesion induced by TNF-a in endothelial cells or inhibition of the release of superoxide anions induced by TNF-a with respect to neutrophils or inhibition of the mitogenic activity of TNF-a in fibroblasts of the dermis. For a substance to be recognized as an antagonist of the release and / or synthesis of histamine, cytokines or TNF-a, it must respond to one of the following characteristics: - inhibition of histamine release by mast cells stimulated by the compound 48/80 or stimulated by a calcium ionophore (A23 187) - inhibition of the release of cytokines or TNF-a by monocytes (U937 cells) differentiated by a phorbol ester (PMA). Antagonists of the histamine Hl receptors useful in the invention are those conventionally used in the treatment of allergic and anaphylactic conditions as well as those for combating transport diseases. These compounds can be, for example, diethylene diamine derivatives such as cinnarizine, cyclizine; aminopropane derivatives such as dexchlorpheniramine, tripolidine; the phenothiazine derivatives such as promethazine, alimemazine; as well as the compounds cited on pages 116 to 118 of the Joseph R. Prous book, The Year's Drug News, Therapeutic Targets, edition 1994, Prous Science Publishers such as cetrizine HCl, ebastine, loratadine, setastine HCl. Inhibitors of histamine release are in particular oxygenated or sulfur-containing heterocyclic compounds such as furan derivatives, benzofuran derivatives, thiophene derivatives and benzothiophene derivatives, optionally containing nitrogen-containing substituents, such as those described in the documents US-A-4931459, US-A-4910317 and EP-A-299457, and more especially the alkoxy- and / or aryloxy-tetrazol-yl-benzofuran-carboxamides or the alkoxy- and / or aryloxy-tetrazolyl-benzothiophene-carboxamides . As an example, there can be mentioned 5-methoxy-3-phenoxy-N-lH-tetrazol-5-yl-benzothiophene-2-carboxamide, 5-methoxy-3- (1-methylethoxy) -N-lH-tetrazol-5-yl- benzothiophene-2-carboxamide, 6-methoxy-3- (1-methylethoxy) -N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide, 5-methoxy-3- (1-ethylethyl) -N-lH- tetrazol-5-yl-benzothiophene-2-carboxamide, 3-benzyloxy-5-methoxy-N-1H-tetrazol-5-yl-benzothiophene-2-carboxamide and 5-methoxy-3-phenoxy-N-lH-tetrazole 5-yl-benzothiophene-2-carboxamide. Among cytokine antagonists, for example, an interleukin-1 release antagonist which can be used in the invention, which may be auranofin or SKF-105809 or an antagonist of interleukin-1 synthesis, which may be lactoferrin. Antagonists of TNF-α receptors and inhibitors of the release and / or synthesis of TNF-α useful in the invention are in particular lyophilin, A802715, sulfasalazine. Antagonists of hisne, cytokines and TNF-a can be synthesized or extracted from natural products (plants or animals). The hisne, cytokine and TNF-α antagonists can be used according to the invention, separately or in association, alone or as a mixture. The amount of compound that decreases the synthesis, release and / or activity of at least one mediator of the inflammation contained in the composition of the invention is of course a function of the desired effect and can therefore vary to a large extent. To give an order of magnitude, the cosmetic composition of the invention may contain a compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation in an amount representing 0.0001% to 5% of the total weight of the composition and preferably in an amount representing 0.001% to 2% of the total weight of the composition. To give an order of magnitude, the pharmaceutical composition of the invention may contain a compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation in an amount representing 0.0001% to 20% of the total weight of the composition and preferably in an amount representing 0.01% to 5% of the total weight of the composition. Whatever the form of the composition according to the invention, the amount of extract of at least one non-photosynthetic filamentous bacterium contained in the composition of the invention is of course a function of the desired effect. This also depends on the form of the extract used in the composition (aqueous extract, lyophilized, ...). Therefore this can vary greatly. To give an order of magnitude, the composition is a cosmetic composition may contain an extract of at least one non-photosynthetic filamentous bacterium in an amount representing 0.0001% to 5% of the total weight of the composition and preferably in an amount representing from 0.001% to 1% of the total weight of the composition. To give an order of magnitude, the composition is a pharmaceutical composition may contain an extract of at least one non-photosynthetic filamentous bacterium in an amount representing 0.0001% to 10% of the total weight of the composition and preferably in an amount representing from 0.01% to 5% of the total weight of the composition. The bacterial extract can be used in a composition that must be ingested, injected or applied to the skin (in all skin areas of the body), hair, nails or mucous membranes (buccal, jugal, gingival, genital, anal, conjunctive). Depending on the form of administration, this composition can be presented under all galenic forms normally used. For a topical application on the skin, the composition may have the particular form of aqueous solution or oily suspension or dispersion of the lotion or serum type, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersing a fatty phase in a aqueous phase (H / E) or inversely (E / H), or of suspensions or emulsions of soft consistency of the type cream or aqueous or anhydrous gel, or even microcapsules or microparticles, or vesicular dispersions of ionic and / or nonionic type. These compositions are prepared according to the usual methods. These can also be used for hair in the form of aqueous, alcoholic or hydroalcoholic solutions, or in the form of creams, gels, emulsions, foams or even in the form of aerosol compositions also containing a pressurized propellant. For injection, the composition may be in the form of an aqueous lotion, an oily suspension or in the form of a serum. For the eyes, it can be presented in the form of drops and for ingestion, it can be presented in the form of capsules, granules, syrups or tablets. The amounts of the different constituents of the compositions according to the invention are those conventionally used in the domains considered. These compositions are in particular cleaning, protective, treatment or care creams for the face, for the hands, for the feet, for the large anatomical folds or for the body (for example day creams, night creams, creams make-up removers, base creams, sunscreen creams), base color fluids, make-up removing milks, body care or care milks, sun-protection milks, lotions, gels or foams for skin care, such as cleaning lotions, sunscreen lotions , artificial tanning lotions, bath compositions, deodorant compositions containing a bactericidal agent, gels or aftershave lotions, epilating creams, compositions against insect bites, anti-pain compositions, compositions for treating certain skin diseases such as eczema, rosaduras, psoriasis, lichen, severe itching. The compositions according to the invention can also consist of solid preparations consisting of cleaning soaps or bars. The compositions may also be packaged in the form of an aerosol composition also containing a pressurized propellant. The bacterial extract used according to the invention can also be incorporated in various compositions for hair care, and particularly shampoos, lotions, lotions for putting in folds, lotions, styling creams or gels, dye compositions (in particular oxidation dyes). optionally in the form of coloring shampoos, restructuring lotions for the hair, permanent compositions (in particular compositions for the first stage of a permanent), lotions or gels against hair loss, anti-parasitic shampoos, etc. The compositions may also be of buccal-dental use, for example a toothpaste. In this case, the compositions may contain adjuvants and additives customary for compositions for oral use and in particular surface-active agents, thickening agents, wetting agents, polishing agents such as silica, various active ingredients such as fluorides, in particular sodium fluoride. , and optionally sweetening agents such as sodium saccharinate. When the composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight with respect to the total weight of the composition. The oils, waxes, emulsifiers and co-emulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic domain. The emulsifier and coemulsifier are present, in the composition, in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 20% by weight with respect to the total weight of the composition. The emulsion may also contain lipid vesicles. When the composition is an oily gel or solution, the fatty phase may represent more than 90% of the total weight of the composition. In a known manner, the cosmetic composition can also contain adjuvants customary in the cosmetic domain, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and coloring materials. The amounts of these different adjuvants are those conventionally used in the cosmetic domain, and for example from 0.01% to 10% of the total weight of the composition. These adjuvants, according to their nature, can be introduced in the fatty phase, in the aqueous phase and / or in the lipid spherules. As oils or waxes useful in the invention, mention may be made of mineral oils (petrolatum oil), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils (Purcellin oil) , silicone oils or waxes (cyclomethicone) and fluorinated oils (perfluoropolyethers), beeswax, carnauba or paraffin waxes. It is possible to add to these oils fatty alcohols and fatty acids (stearic acid). As emulsifiers useful in the invention, mention may be made, for example, of glycerol stearate, polysorbate 60 and the mixture PEG-6 / PEG-32 / Glycol stearate sold under the name of Tefose "63 by the company Gettefosse. Minor alcohols, in particular ethanol and isopropanol, propylene glycol may be mentioned as the hydrophilic gelling agents useful in the invention, there may be mentioned carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides such such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, there may be mentioned modified clays such as benthones, metal salts of fatty acids such as aluminum stearates and hydrophobic silica, ethylcellulose, polyethylene.The composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugar ares and sugar derivatives, water-soluble vitamins, plant extracts and hydroxy acids. As active lipophilics, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, essential oils, salicylic acid and its derivatives can be mentioned. According to the invention, it is possible, if possible, to associate at least one extract of at least one non-photosynthetic filamentous bacterium with other active agents intended in particular for the prevention and / or treatment of cutaneous disorders. Among these active agents, mention may be made, by way of example: - agents that modulate differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, oestrogens such as oestradiol, kojic acid or hydroquinone; - antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class; - antiparasitic agents, in particular, metroindazole, crotamiton or pyrethrinoids; antifungals, in particular compounds belonging to the class imidazoles such as econazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamines family, such as terbinafine, or even octopirox; - antiviral agents such as acyclovir; - steroidal antiinflammatory agents, such as hydrocortizone betamethasone valerate or clobetasol propionate, or non-steroidal anti-inflammatory agents such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid; - anesthetic agents such as lidocaine hydrochloride and its derivatives; antipruritic agents such as tenaldine, trimeprazine or cyproheptadine; - ceratolytic agents such as alpha- and beta-hydroxycarboxylic acids or beta-ketocarboxylic acids, their salts, amides or esters or more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and, in general, fruit acids, and n-octanoyl-5-salicylic acid; - anti-free radical agents, such as alpha-tocopherol or its esters, superoxide dismutases, certain metal chelators or ascorbic acid and their esters; - anti-seborrheic drugs such as progesterone; - antipeliculars such as octopirox or zinc pyrithione; - anti-acne drugs such as retinoic acid or benzoyl peroxide. Thus, according to a particular embodiment, the invention relates to the use of at least one extract of at least one non-photosynthetic filamentous bacterium in a composition containing at least one agent selected from the antibacterial, antiparasitic, antifungal, antiviral agents , anti-inflammatories, antipruritic agents, anesthetics, anti-free radicals, antiseborrhoeic agents, antipyretics, anti-acne agents and / or agents that modulate differentiation and / or proliferation and / or cutaneous pigmentation. The subject of the present invention is also a cosmetic treatment process for the purpose of reducing the irritant effect of a cosmetic composition, characterized in that a composition is applied on the skin, on the hair, and / or on the mucous membranes. as described above. The cosmetic treatment process of the invention can be implemented in particular by applying the hygienic or cosmetic compositions as defined above, according to the technique of usual use of these compositions. For example: application of creams, gels, serums, lotions, makeup removal milks or anti-solar compositions on the skin or on dry hair, application of a lotion for hair on wet hair, of shampoos, or the application of toothpaste on the gums. The following examples and compositions illustrate the invention without limiting it in any way. In the compositions the proportions indicated are percentages by weight.

Example L: Preparation of a vitreous plant phylophosis; The strain of Vitreoscilla filiformis (ATCC 15551) was cultured according to the procedure described in the patent application WO-A-93,00741. The culture was carried out at 26 ° C for at least 48 hours until obtaining a suitable cell concentration corresponding to an optical density at 600 nm greater than or equal to 1.5. The strain is reseeded at 2% v / v in fresh medium every 48 hours until obtaining a stable culture. A liter Erlenmeyer containing 200 ml of fresh medium was then seeded with 4 ml of the preceding culture. The Erlenmeyer culture was carried out at 26 ° C on a stirred culture mass at 100 revolutions / minute. The tank foot thus obtained serves as an inoculum to a fermenter of 10 1. The growth is carried out at 26 ° C, pH 7, 100 rounds / minute and p02 = 15%. After 48 hours of growth, the biomass was transferred to a fermentor of 600 useful liters, to be cultivated in the same conditions. After 48 h of growth the cells were harvested. The biomass was then concentrated 50 times approximately by centrifugation. The concentrate was autoclaved at 121 ° C for 40 minutes. After cooling, two phases appeared. The liquid phase supernatant was then filtered at 0.22 μm to remove the particles. This extract is usable in such a state (aqueous form) or can be lyophilized following the classical techniques (lyophilized form).

Example 2: Measurement of receptor affinity of the bacterial extract (example 1, aqueous form) for the human NKl receptor (human substance P receptor): TO); Receiver affinity: The measurement of receptor affinity of the bacterial extract by the human NKl receptor was carried out according to the method described in the article: Heuillet, E. et al., J. Neurochem., 6_Q, 1993, 868-876. The extract was tested at concentrations of 1%, 5% and 10%. During each experiment, the reference molecule of the receptor studied ([Sar9, Met (02) 1L] -SP, analogous to substance P described by Heuillet, E. (Heuillet, E. et al., J. Neurochem., £ £, 1993, 868-876)) was tested in parallel to 8 concentrations (n = 2), to obtain a standard curve to validate the experiment. The following is obtained: 9% fixation for the extract of the example 1% 27% fixation for the extract of example 1 to 5% 91% fixation for the extract of example 1 to 10% The results of this experiment demonstrate an affinity of the bacterial extract in aqueous form for the human substance P receptor from the concentration of 1%. The affinity curve plotted from the results obtained shows 50% displacement of the natural ligand (IC50) for the bacterial extract at the 6.7% concentration.

Bl: In vitro functional test: An in vitro functional test performed on human NKl receptors (receptors of human substance P) present in the smooth muscles of isolated intestine (ileum) was performed to demonstrate the substance P antagonist characteristic of the bacterial extract . The in vitro experiments were carried out according to the method described by Dion et al. (Life Sciences, 41, 1987, 2269-2278) and Patacchini et al. (Eur. J. Pharmacol., 215, 1992, 93-98). After installation in the experimental vats, the tissues (smooth muscles) were subjected to an initial tension of 1 g. An equilibrium period of at least 60 minutes, in the course of which the physiological solution was renewed several times and the initial tension was readjusted, followed by observation before the addition of the extract. The experiments were performed in the continuous presence of atropine (3.106 M), pyrilamine (3.10"6 M) and indomethacin (10" SM) to get rid of the indirect effects of mediators used during the stimulation of other types of receptors present in this tissue. Each preparation was initially stimulated by a substance P antagonist: [Sar9, Met (02) ll] -SP, at the concentration of 10aM to obtain a "control" contractile response, then the physiological solution was completely renewed. This operation was repeated every 40 minutes in the presence of increasing concentrations of bacterial extract, each one being added 30 minutes before the [Sar9, Met (02) 1X] -SP. A 50% inhibition of the activity of [Sar9, Met (02) 1X] -SP was obtained at the 5% concentration in extract.

Cl: Functional Bnsa? In vivo: A functional in vivo test was performed on a model of neurogenic inflammation to demonstrate the antagonistic character of substance P of the bacterial extract. The in vivo experiments were performed according to the method described by Xu X.J. and collaborators (Neurosciences, 1991, 42, 731-737). The test consists of causing a neurogenic inflammation by the antidromic stimulus of the saphenous nerve in the anesthetized animal. This nerve innervates the cutaneous territories of the hind legs. The separate stimulation causes the release from the nerve endings of substance P, responsible in part for the neurogenic inflammation. Neurogenic inflammation is quantified by measuring tissue permeability in Evans blue, a marker of tissue extravasation of plasma albumin that occurs during the course of inflammation. This reference model was used for the in vivo search of substance P antagonists. The bacterial extract in its aqueous form, administered diluted 1/100 *, causes a statistically significant 51% decrease in neurogenic inflammation.

Conclusions: The bacterial extract has an affinity for the substance P receptor and exerts a substance P antagonist activity.

Example 3: Evaluation of the tranquilizing effect of an extract of Vitreoscilla filiformis: TO); Protocol; 1) Selection of subjects 25 subjects of sensitive skin were selected by a dermatologist according to the criteria of the lactic acid test (K. Lammintausta et al., Dermatoses, 1988, £, pages 45-49, T. Agner and J. Serup, Clinical and Experimental Dermatology, 1989, 14, pages 214-217). The chosen subjects are subjects who have a moderate reactivity and subjects who have a strong reactivity. 2) Development of the trial A complete treatment was performed for each subject. This treatment was carried out twice a day and comprises successively: - a cleaning phase carried out following the custom of the subject with the help + of a cleansing cream (formula A) in the case of the use of water for cleaning the skin; + of a cleaning milk (formula B) when the cleaning is without water; - use of a care lotion (formula C) applied after cleaning on perfectly dry skin; - use of a care cream (formula D) applied after the lotion. The test was developed in a time of 4 weeks with control of skin reactivity:. before the first application of the Ti products. after 7 days of treatment, T8. after 2 weeks of treatment, T15 . after 2 weeks of treatment, T29 The control was carried out according to the following procedure: The application was carried out blindly. - application in a naso-genian contralateral sulcus of a cotton soaked with 0.1 ml of a 10% aqueous solution of lactic acid. This cotton was passed 10 times in a row by the naso-genian furrow. - application on the naso-genian contralateral sulcus of a cotton soaked with 0.1 ml of physiological saline. This cotton was passed 10 times in a row by the naso-genian furrow. - evaluation of the itching sensation in each naso-genian sulcus by the same subject in the course of the first 30 seconds, of 2 and 5 minutes attributing a note according to the following scale: 0 = no itching 1 = light itching 2 = itching moderate 3 = severe itching The marker was established by obtaining the differences of the total markers sums (30 sec, 2 and 5 mn) for each furrow between the side treated by the lactic acid and the other side treated with physiological saline, or sea: Marker = (sum of lactic acid markers) - (sum of saline markers).

B): Compositions used for the test: (Formula A): Cleansing cream Extract from Example 1 (in its 0.05 lyophilized form) Cetyl alcohol 2.00 Glycerol stearate 2.00 Stearic acid 2.00 Polyglyceryl-3-hydroxylauryl ether 5.00 Codex mineral oil 12.00 Carbomer 0.35 Sodium hydroxide 0.15 Perfume qsp Methyl paraben 0.20 Sterile demineralised water qsp 100.00 (Formula B) Cleansing milk Extract from Example 1 (in its 0.05 lyophilized form) Carbomer 0.40 Sodium hydroxide 0.10 Codex mineral oil 5.00 Glycerol stearate 1.00 Cetyl alcohol 0.50 PEG 100 stearate 0.80 Methyl paraben 0.20 Perfume qsp Sterile demineralized water qsp 100.00 (Formula B) Cleansing milk Extract from Example 1 (in its 0.05 lyophilized form) Glycerol 2.00 Methyl paraben 0.15 Perfume qsp Sterile demineralised water qsp 100.

(Formula D): Cui ado cream Extract from example 1 (in its 0.05 lyophilized form) glycerol stearate 1.00 PEG 100 stearate 1.00 Stearic acid 1.00 Cetyl Alcohol 2.00 Soybean oil 3.00 Palm oil 2.00 Cyclomethicone 2.00 Dimeticone 1.00 Polyacrylamide 0.20 Glicerol 3.00 Methyl paraben 0.20 Perfume qsp Sterile demineralized water qsp 100.00 Cl: Results (in arbitrary units) 15 n: -not provide it. A very strong decrease in skin sensitivity was observed from the first week of treatment, a decrease that continued until the conclusion of treatment.

Example 4: Preparation of an extract of Iris paluda: The undifferentiated cells of Iris pallida grown in vitro under axenic conditions were recovered after Erlenmeyer culture or in a fermenter by filtration on a 50 μm sieve. To 55 g of fresh material thus obtained, 27.5 ml of demineralized water were added. The whole was crushed (Potter, Ultra Turax ...) in Turax at 24,000 R / min for 1 minute at 4 ° C (ice bath). The crushed was centrifuged from 15 to 10000 G at 4 ° C. The supernatant was filtered at 0.22 μm (sterilizing filtration). The extract thus prepared was preserved at 4 ° C. It includes approximately 15 g of dry matter per liter. If the plant material is of the whole plant, the fresh matter to be treated is brought in according to the dry weight to be put in the same conditions of extraction as by in vitro. The different parts of the plant were extracted according to the relative weight of each part of it. The cold treatment allows to freeze the enzymatic activities, the sterilizing filtration prevents the degradation of the active agents by the microorganisms of the environment. Finally, the water vehicle is compatible with ex vivo receptors and facilitates cosmetic or pharmaceutical formulations.

Example 5: Examples of formulations illustrating the invention and particularly the compositions according to the invention associating at least one extract of at least one non-photosynthetic filamentous bacterium and one product of irritant effect. These compositions were obtained by simple mixing of the different components.

Composition 1: Cleansing lotion for the face Extract of Example 1 (in its 0.01 lyophilized form) Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 2: Gel for the care of the face Extract of example l (in its 0.05 lyophilized form) Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 3: Cream for the care of the face (emulsion of oil in water) Extract from example 1 (in its aqueous form 2.00) glycerol stearate 2.00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1.40 Triethanolamine 0.70 Carbomer 0.40 Liquid fraction dismantles Karite 12.00 Perhydrosqualene 12.00 Antioxidant 0.05 Perfume 0.50 Conservative 0.30 Water qsp 100% Composition 4: Shampoo Extract from Example 1 (in its aqueous form 1.00) Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Perfume 0.50 Conservative 0.30 Water qsp 100% Composition 5: Cream for anti-wrinkle care for the face (oil / water emulsion) Extract from Example 1 (in its 0.05 lyophilized form) Glycerol stearate 2. .00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1. .40 N-octanoyl-5-salicylic acid 0.50 Triethanolamine 0.70 Carbomer 0. .40 Liquid fraction of Karite butter 12.00 Perhydrosqualene 12.00 Antioxidant 0. .05 Perfume 0. .50 Conservative 0. .30 Water qsp 100% Composition 6: Anti-pain gel Extract from Example 1 (in its 0.03 lyophilized form) Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Antioxidant 0.05 Lidocaine hydrochloride 2.00 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 7: Cream for the care of solar erythema (emulsion of oil in water) Extract from example 1 (in its aqueous 0.75 form) glycerol stearate 2.00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1.40 Glycyrrhetinic acid 2.00 Triethanolamine 0.70 Carbomer, 0.40 Liquid fraction of Karite butter 12.00 Sunflower oil 10.00 Antioxidant 0.05 Perfume 0.50 Conservative 0.30 Water qsp 100% Composition 8: Gel for the treatment of acne Extract from Example 1 (in its aqueous 0.50 form) All trans retinoic acid 0.05 Hydroxypropyl cellulose (Klucel H) 1.00 Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 9: Locióp to eliminate scars due to acne Extract from Example 1 (in its freeze-dried form 0.025) Glycolic acid 50.00 Hydroxypropylcellulose (Klucel H) 0.05 NaOH qsp pH = 2.80 Ethanol qsp 100% Conservative 0.30 Composition 10: Gel for the care of the face Extract from example 1 1 () .00 Extract from example 4 0. .50 Hydroxypropylcellulose (Klucel H 1, .00 sold by the Hercules Company) Antioxidant 0. .05 Isopropanol 4 () .00 Conservative 0. .30 Water qsp 100 % Composition 10: Cleansing lotion for the face Excerpt from Example 1 5.00 Excerpt from example 4 0.10 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 12: Cream for face care (oil in water emulsion) Excerpt from Example 1 7.00 Excerpt from example 4 1.00 glycerol stearate 2.00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1.40 Triethanolamine 0.70 Carbomer 0.40 Dehydrated liquid fraction of Karite 12.00 Perhydrosqualene 12.00 Antioxidant 0.05 Conservative 0.30 Water qsp 100% Composition 13: Shampoo Excerpt from example 1 2.00 Excerpt from example 4 0.50 Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Perfume 0.50 Conservative 0.30 Water qsp 100% Composition 14: Lotion to eliminate scars due to acne Excerpt from Example 1 8.00 Excerpt from example 4 1.00 Glycolic acid 50.00 Hydroxypropylcellulose (Klucel H 0.05 sold by the Hercules Company) NaOH qsp pH = 2.8 Ethanol qsp 100% Conservative 0.30 Composition 15: Gel for the treatment of acne Excerpt from Example 1 8.00 Excerpt from Example 4 1.00 Acid all trans retinoic 0.05 Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Society) Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 16: Anti-pain gel Extract from example 1 0.50 Excerpt from example 4 10.00 Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Antioxidant 0.05 Lidocaine hydrochloride 2.00 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 17: Cream for the care of solar erythema (oil in water emulsion) Excerpt from Example 1 5.00 Excerpt from example 4 1.00 glycerol stearate 2.00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1.40 Glycyrrhetinic acid 2.00 Triethanolamine 0.70 Carbomer 0.40 Liquid fraction of Karite butter 12.00 Sunflower oil 10.00 Antioxidant 0.05 Perfume 0.50 Conservative 0.30 Water qsp 100% Composition 18: Anti-wrinkle care cream for the face (oil / water emulsion) Excerpt from Example 1.00 Excerpt from example 4 8.00 glycerol stearate 2.00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1.40 N-octanoyl-5-salicylic acid 0.50 Triethanolamine 0.70 Carbomer 0.40 Liquid fraction of Karite butter 12.00 Perhydrosqualene 12.00 Antioxidant 0.05 Perfume 0.50 Conservative 0.30 Water qsp 100% Composition 19: Cleansing lotion for the face Excerpt from Example 1.00 Strontium Chloride 5.00 Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 20: Gel for the care of the face Extract from example 1 0.50 Vichy thermal water 10.00 Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 21: Cream for face care (oil-in-water emulsion) Excerpt from example 1 1. .00 Auranofin 0. .10 Glycerol stearate 2., 00 Polysorbate 60. { Tween 60 sold by 1.00 the ICI Society) Stearic acid 1. .40 Triethanolamine 0.70 Carbomer 0. .40 Liquid fraction of Karite butter 12.00 Perhydrosqualene 12.00 Antioxidant 0., 05 Conservative 0., 30 Water qsp 100% Cotforming 22: Shampoo Extract from example 1 0.50 Strontium Chloride 5.00 Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Company) Conservative 0.30 Water qsp 100% Composition 23: Lotion to eliminate scars due to acne Excerpt from Example 1 1.00 HOE 140 0.05 Glycolic acid 50.00 Hydroxypropylcellulose (Klucel H 0.05 sold by the Hercules Company) NaOH qsp pH = 2.8 Ethanol qsp 100% Conservative 0.30 Composition 24: Gel for the treatment of acne Excerpt from example 1 2.00 CGRP 8-37 0.50 Acid all trans retinoic 0.05 Hydroxypropylcellulose (Klucel H 1.00 sold by the Hercules Society) Antioxidant 0.05 Isopropanol 40.00 Conservative 0.30 Water qsp 100% Composition 25: Anti-pain gel Extract from example 1 0, .50 Spatida II 0, .05 Hydroxypropylcellulose (Klucel H 1. .00 sold by the Hercules Company) Antioxidant 0, .05 Lidocaine hydrochloride 2. .00 Isopropanol 40.00 Conservative 0. .30 Water qsp 100% Composition 26: Cream for the care of solar erythema (oil in water emulsion) Excerpt from example 1 1., 00 Vichy thermal water 10.00 Glycerol stearate 2. 00 Polysorbate 60 (Tween 60 sold by 1., 00 the ICI Society) Stearic acid 1., 40 Glycyrrhetinic acid 2., 00 Triethanolamine 0.70 Carbomer 0., 40 Liquid fraction of Karite butter 12.00 Sunflower oil 10.00 Antioxidant 0., 05 Perfume 0., 50 Conservative 0., 30 Water qsp 100% Composition 27: Cream for anti-wrinkle care for the face (oil / water emulsion) Excerpt from Example 1 1.00 Lactoferrin 1.00 glycerol stearate 2.00 Polysorbate 60 (Tween 60 sold by 1.00 the ICI Society) Stearic acid 1.40 N-octanoyl-5-salicylic acid 0.50 Triethanolamine 0.70 Carbomer, 0.40 Liquid fraction of Karite butter 12.00 Perhydrosqualene 12.00 Antioxidant 0.05 Perfume 0.50 Conservative 0.30 Water qsp 100%

Claims (30)

1. Use of at least one extract of at least one bacterium belonging to the order of the Beggiatoals as an antagonist of substance P in a cosmetic composition or for the preparation of a pharmaceutical composition.

2. Use of at least one extract of at least one bacterium belonging to the order of the Beggiatoals in a cosmetic composition or for the preparation of a pharmaceutical composition intended to treat the disorders associated with an excess of synthesis and / or release of substance P.

3. Use according to any of claims 2, characterized in that the composition is intended to treat disorders of the central nervous system, respiratory problems, allergic syndromes, inflammation, pain, gastrointestinal disorders, skin disorders, fibrosis , alterations in the maturation of collagen, cardiovascular problems, vasospastic problems, immune disorders and / or urinary tract problems.

4. Use according to any of claims 1 to 3, characterized in that the cosmetic or pharmaceutical composition is intended to treat sensitive skin.

5. Use according to any of claims 1 to 4, characterized in that the cosmetic or pharmaceutical composition is intended to prevent and / or combat skin irritations and / or herpes and / or erythema and / or sensations of dysesthesia and / or Irritation sensations and / or pruritus of the skin and / or mucous membranes.

6. Use according to any of claims 1 to 5, characterized in that said bacterium belongs to the genus Beggiatoa, Vitreoscilla, Flexithrix or Leucothrix.

7. Use according to claim 6, characterized in that said bacterium is selected from strains of Vitreoscilla filiformis.

8. Use of a cosmetic composition according to any of claims 1 to 7, characterized in that said bacterial extract is used in an amount representing 0.0001% to 20% of the total weight of the composition and preferably in an amount representing 0.001 % to 10% of the total weight of the composition.

9. Use of a pharmaceutical composition according to any of claims 1 to 7, characterized in that said bacterial extract is used in an amount representing 0.0001% to 30% of the total weight of the composition and preferably in an amount representing 0.05 % to 20% of the total weight of the composition.

10. Use according to one of claims 1 to 9, characterized in that the cosmetic or pharmaceutical composition also contains at least one product with an irritant effect.

11. Use according to one of claims 1 to 10, characterized in that the cosmetic or pharmaceutical composition also contains at least one cell extract of at least one plant of the Irididaceae family.

12. Use according to one of claims 1 to 11, characterized in that the cosmetic or pharmaceutical composition also contains at least one compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation.

13. Cosmetic or pharmaceutical composition, characterized in that it comprises, in a cosmetically or pharmaceutically acceptable medium, an extract of at least one bacterium belonging to the order of the Beggiatoals and at least one product with an irritant effect.

14. Cosmetic or pharmaceutical composition, characterized in that it comprises, in a cosmetically or pharmaceutically acceptable medium, an extract of at least one bacterium belonging to the order of Beggiatoal and an extract of cells of at least one plant of the Irididaceae family.

15. Cosmetic composition according to claim 14, characterized in that said extract of Iridáceas is used in an amount representing 0.001% to 20% of the total weight of the composition and preferably in an amount representing 0.01% to 10% of the weight total of the composition.

16. Pharmaceutical composition according to claim 14, characterized in that said extract of Iridáceas is used in an amount representing 0.01% to 30% of the total weight of the composition and preferably in an amount representing 0.5% to 20% of the weight total of the composition.

17. Cosmetic or pharmaceutical composition, characterized in that it comprises, in a cosmetically or pharmaceutically acceptable medium, an extract of at least one bacterium belonging to the order of Beggiatoals and a compound that decrease the synthesis, release and / or activity of at least one mediator of inflammation.

18. Composition according to claim 17, characterized in that the compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation is chosen from the agonists of substance P and / or CGRP, NO inhibitors. -siptase, bradykinin antagonists, cytokine antagonists, histamine antagonists, α-tumor necrosis factor antagonists (TNFα).

19. Composition according to claim 18, characterized in that the antagonists are receptor antagonists.

20. Composition according to any of claims 18 or 19, characterized in that the substance P antagonist is chosen from substances that provide a decrease in plasma extravasation through the vascular wall induced by capsaicin or by antidromic nerve stimulation and the substances that cause an inhibition of the contraction of the smooth muscles induced by the administration of the substance P.

21. Composition according to any of claims 10 to 20, characterized in that the substance P antagonist is chosen from peptides, compounds containing at least one heterocycle, nitrogen compounds containing at least one benzene ring, salts of monovalent, divalent and trivalent cations , hot springs and their mixtures.

22. Composition according to any of claims 18 or 19, characterized in that the CGRP antagonist is chosen from substances that ensure a decrease in vasodilation induced by capsaicin or by an antidromic electrical stimulation (applied to an afferent nerve) and / or an inhibition of the release of CGRP by the sensitive nerve fibers and the substances that cause an inhibition of smooth muscle contraction of the vas deferens induced by CGRP.

23. Composition according to claim 18, characterized in that the inhibitor of NO-synthase is chosen from substances that allow in situ in man to partially or even completely inhibit the synthesis of nitrogen monoxide (NO).

24. Composition according to any of claims 18 or 19, characterized in that the bradykinin antagonist is chosen from the compounds that inhibit the synthesis and / or accelerate the catabolism of bradykinin, the compounds that neutralize bradykinin, the compounds that block bradykinin receptors such as those that interfere with the effects of bradykinin by its binding to the receptor thereof (Bl or B2), compounds that inhibit the synthesis of bradykinin receptors or compounds that intervene by decreasing the signal transduced by bradykinin

25. Composition according to any of claims 18 or 19, characterized in that the histamine, cytokine or TNF-α antagonist is a substance chosen from antagonists of histamine receptors, cytokines or TNF-α, or between antagonists of the release and / or synthesis of histamine, cytokines or TNF-a.

26. Cosmetic composition according to any of claims 17 to 25, characterized in that the compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation is in an amount representing 0.0001% to 5% of the weight total of the composition and preferably in an amount representing from 0.001% to 2% of the total weight of the composition.

27. Pharmaceutical composition according to any of claims 17 to 25, characterized in that the compound that decreases the synthesis, release and / or activity of at least one mediator of inflammation is in an amount representing 0.0001% to 20% by weight total of the composition and preferably in an amount representing 0.01% to 5% of the total weight of the composition.

28. Cosmetic composition according to any of claims 13 to 27, characterized in that said bacterium is in an amount representing from 0.0001% to 5% of the total weight of the composition and preferably in an amount representing 0.001% to 1% of the total weight of the composition. total weight of the composition.

29. Cosmetic composition according to any of claims 13 to 27, characterized in that said bacterium is in an amount representing 0.0001% to 10% of the total weight of the composition and preferably in an amount representing 0.01% to 5% of the total weight of the composition. total weight of the composition.

30. Cosmetic treatment method, characterized in that a cosmetic composition as defined in any of claims 13 to 15 or 17 to 26 or 28 is applied on the skin, on the hair and / or on the mucous membranes.